Dengue Branch, Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, San Juan, PR, USA.
J Travel Med. 2010 Jan-Feb;17(1):8-14. doi: 10.1111/j.1708-8305.2009.00374.x.
As the incidence of dengue increases globally, US travelers to endemic areas may be at an increased risk of travel-associated dengue.
Data from the US Centers for Disease Control and Prevention's laboratory-based Passive Dengue Surveillance System (PDSS) were used to describe trends in travel-associated dengue reported from January 1, 1996 to December 31, 2005. The PDSS relies on provider-initiated requests for diagnostic testing of serum samples via state health departments. A case of travel-associated dengue was defined as a laboratory-positive dengue infection in a resident of the 50 US states and the District of Columbia who had been in a dengue-endemic area within 14 days before symptom onset. Dengue infection was confirmed by serologic and virologic techniques.
One thousand one hundred and ninety-six suspected travel-associated dengue cases were reported-334 (28%) were laboratory-positive, 597 (50%) were laboratory-negative, and 265 (22%) were laboratory-indeterminate. The incidence of laboratory-positive cases varied from 1996 to 2005, but had an overall increase with no significant trend (53.5 to 121.3 per 10(8) US travelers, p = 0.36). The most commonly visited regions were the Caribbean, Mexico and Central America, and Asia. The median age of laboratory-positive cases was 37 years (range: <1 to 75 y) and 166 (50%) were male. Of the 334 laboratory-positive cases, 41 (12%) were hospitalized, and 2 (1%) died.
Residents of the US traveling to dengue-endemic regions are at risk of dengue infection and need to be instructed on appropriate prevention measures prior to travel. Especially in light of the potential transmissibility of dengue virus via blood transfusion, consistent reporting of travel-associated dengue infections is essential.
随着全球登革热发病率的上升，前往流行地区的美国旅行者旅行相关登革热的风险可能会增加。
使用美国疾病控制与预防中心基于实验室的被动登革热监测系统（PDSS）的数据来描述 1996 年 1 月 1 日至 2005 年 12 月 31 日报告的旅行相关登革热的趋势。PDSS 依赖于州卫生部门发起的对血清样本进行诊断检测的请求。旅行相关登革热病例定义为在 50 个美国州和哥伦比亚特区的居民中，在症状出现前 14 天内曾在登革热流行地区的实验室阳性登革热感染。登革热感染通过血清学和病毒学技术得到确认。
报告了 1196 例疑似旅行相关登革热病例-334 例（28％）实验室阳性，597 例（50％）实验室阴性，265 例（22％）实验室不确定。1996 年至 2005 年期间，实验室阳性病例的发病率有所不同，但总体呈上升趋势，无明显趋势（每 108 名美国旅行者中有 53.5 至 121.3 例，p = 0.36）。最常访问的地区是加勒比海、墨西哥和中美洲以及亚洲。实验室阳性病例的中位年龄为 37 岁（范围：<1 至 75 岁），其中 166 例（50％）为男性。在 334 例实验室阳性病例中，有 41 例（12％）住院，2 例（1％）死亡。
前往登革热流行地区的美国居民有感染登革热的风险，在旅行前需要接受有关适当预防措施的指导。特别是鉴于登革热病毒通过输血传播的可能性，必须持续报告旅行相关登革热感染。
